Welcome to our dedicated page for Walgreen Boots SEC filings (Ticker: WBA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Struggling to spot prescription-margin shifts or opioid litigation charges buried inside Walgreens Boots Alliance’s lengthy reports? The company’s global mix of U.S. pharmacy retail, Boots UK, and Alliance Healthcare distribution makes every disclosure dense and data-heavy. Stock Titan’s AI decodes each page so you don’t have to.
Open a Walgreens Boots Alliance annual report 10-K simplified and our platform pinpoints script volume trends, reimbursement rate changes, and segment profitability in seconds. Need the latest Walgreens Boots Alliance quarterly earnings report 10-Q filing? Real-time feeds pull highlights on store closures, vaccination revenue, and Village Medical partnerships as soon as they hit EDGAR.
For governance questions, the Walgreens Boots Alliance proxy statement executive compensation tab shows how pay ties to prescription growth, while Walgreens Boots Alliance insider trading Form 4 transactions reveal whether pharmacists-turned-executives are buying or selling stock. Every Walgreens Boots Alliance Form 4 insider transactions real-time alert includes AI commentary on transaction size and timing.
- AI-powered summaries translate complex accounting notes into clear language, making understanding Walgreens Boots Alliance SEC documents with AI effortless.
- All filings, always current—from sudden Walgreens Boots Alliance 8-K material events explained to shelf registrations and S-8 plans.
- Practical tools to compare quarter-over-quarter script counts, monitor cash flow swings, and flag opioid settlement reserves.
Whether you’re running an Walgreens Boots Alliance earnings report filing analysis before the bell or scanning a Walgreens Boots Alliance SEC filings explained simply overview, Stock Titan streamlines the entire research workflow. Receive alerts, read expert context, and make confident decisions—all from one page.
Walgreens Boots Alliance (NASDAQ:WBA) filed Definitive Additional Proxy Materials (DEFA14A) tied to its proposed merger with Sycamore Partners’ vehicle Blazing Star.
The filing confirms that the special shareholder meeting will be held on July 11, 2025, when investors will vote on the transaction detailed in the March 6, 2025 merger agreement. CEO Tim Wentworth’s transcript highlights Q3 FY25 progress: cost-savings in U.S. retail pharmacy, improving VillageMD and Shields performance, strong international results and higher cash flow, offset by continuing U.S. retail headwinds.
The Board unanimously recommends a FOR vote. Forward-looking language reiterates multiple risks including financing, regulatory approvals and potential termination fees. No financial terms of the merger or voting tallies are disclosed in this update.
Walgreens Boots Alliance (Nasdaq: WBA) filed its Q3 FY25 10-Q for the quarter ended May 31 2025. The filing confirms three operating segments—United States Retail Pharmacy, International and US Healthcare—and details the ongoing Footprint Optimization Program and Transformational Cost Management Program, which generated asset impairments, lease-related exit costs and severance charges across segments.
Liquidity updates include a new April 2025 Accounts Receivable Revolving Facility and disclosure of $3.6 bn notes due 2025 and $2.125 bn notes due 2026. The company also consolidates a variable-interest entity and notes subsequent-event activity related to its Cencora equity investment.
Management signals continued store rationalization and cost reduction to support US Healthcare growth while addressing near-term refinancing needs.
Walgreens Boots Alliance (Nasdaq: WBA) filed a Form 8-K under Item 2.02 to furnish its fiscal third-quarter 2025 results (quarter ended May 31 2025). A detailed press release is attached as Exhibit 99.1 and incorporated by reference; the body of the 8-K contains no financial tables. The information is "furnished," not "filed," avoiding Section 18 liability. No guidance revisions, strategic transactions or other material events were disclosed. The sole purpose is compliance with Regulation FD—making the earnings release simultaneously available to all investors. The report was signed by CFO Manmohan Mahajan on June 26 2025.
FAQ
What is the current stock price of Walgreen Boots (WBA)?
What is the market cap of Walgreen Boots (WBA)?
What is the core business of Walgreens Boots Alliance?
How does the company generate revenue?
What distinguishes Walgreens Boots Alliance in the healthcare industry?
What is the significance of its global presence?
How does the company enhance the customer experience?
What role does its distribution network play?
How is the company positioned within its competitive landscape?
What are the key elements of its business strategy?
